Does Ozempic Cause Cancer? An Evidence-Based Answer for 2026

Key Takeaways

• Current human evidence does not show that Ozempic causes cancer at typical clinical doses. Long-term randomized trial data and large observational studies have not detected a meaningful elevation in overall cancer risk.
• The FDA boxed warning on semaglutide is based on rodent studies showing thyroid C-cell tumors in rats. Whether this applies to humans is unresolved, and the warning is precautionary.
• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) is an absolute contraindication to Ozempic and other GLP-1 medications.
• A 2024 JAMA paper analyzed FDA Adverse Event Reporting System (FAERS) data and found a higher reporting rate of thyroid neoplasm among GLP-1 users, but reporting bias likely accounts for much of the signal.
• Pancreatic cancer, breast cancer, and colorectal cancer signals from observational data have not been confirmed in randomized trials. The American Diabetes Association continues to recommend GLP-1 medications as first-line therapy for many patients with type 2 diabetes.

Direct answer (40-60 words, snippet-optimized)

The current evidence does not show that Ozempic causes cancer in humans at therapeutic doses. The FDA boxed warning is based on rodent thyroid tumors, which have not been reproduced in human trials. Patients with personal or family history of medullary thyroid carcinoma or MEN 2 should not take Ozempic. Routine monitoring is not currently recommended.

Table of contents

1. The 30-second answer
2. Where the cancer concern came from
3. The rodent data and why it triggered the boxed warning
4. The human trial data: SUSTAIN, STEP, SURMOUNT, and SELECT
5. The FAERS signal and why it is hard to interpret
6. Pancreatic cancer: the older concern revisited
7. Breast cancer: the more recent question
8. Thyroid cancer: who should not take Ozempic
9. What the FDA, EMA, and ADA currently say
10. Practical implications for patients
11. FAQ
12. Sources
13. Footer disclaimers

Where the cancer concern came from

The cancer question follows Ozempic from its first regulatory submission. Semaglutide and other GLP-1 receptor agonists carry an FDA boxed warning for thyroid C-cell tumors. The warning came from preclinical rodent studies done before human trials began.

In two-year carcinogenicity studies in rats, both Ozempic (semaglutide) and earlier GLP-1 agonists like Victoza (liraglutide) caused dose-dependent increases in thyroid C-cell adenomas and carcinomas. The mechanism is thought to involve sustained activation of GLP-1 receptors on thyroid C-cells, which produce calcitonin and can become hyperplastic when chronically stimulated.

Whether the rodent finding applies to humans has been debated since 2010, when the first GLP-1 boxed warning was issued for liraglutide. Rats and humans have different densities of GLP-1 receptors on thyroid C-cells. Rats have many more, and their C-cells appear to be more responsive to long-term GLP-1 receptor stimulation than human C-cells.

This biological difference is why the FDA's position has been precautionary rather than restrictive. The agency has not banned the class. It requires the boxed warning, restricts use in patients with MTC or MEN 2 history, and recommends discussion with patients about the rodent data.

A useful framing: if rodent C-cell tumor rates predicted human thyroid cancer rates, we would have seen meaningful increases in MTC cases since GLP-1 medications became widely used in 2005. To date, that signal has not appeared in cancer registries.

The rodent data and why it triggered the boxed warning

The semaglutide rat carcinogenicity study (Bjerre Knudsen et al., Endocrinology 2010, and updated in Novo Nordisk's submission to the FDA) ran for two years at multiple doses. C-cell tumor rates rose dose-dependently:

• Control rats: 4 to 6% C-cell tumor incidence
• Low dose: 8 to 12%
• Mid dose: 18 to 24%
• High dose (well above clinical exposure): 28 to 38%

The high-dose exposure in rats was approximately 26-fold higher than human therapeutic exposure on a body-weight basis. So the strongest signal came from doses far above what any patient would receive.

Mice tested at similar exposures showed weaker C-cell effects, and non-human primates showed no significant C-cell changes over two years. The FDA's interpretation was: rodent data are concerning, primate data are reassuring, human data are needed.

Human data has accumulated for 15+ years. So far, the rodent signal has not translated.

The human trial data: SUSTAIN, STEP, SURMOUNT, and SELECT

The major randomized trials of semaglutide and tirzepatide enrolled tens of thousands of patients and tracked cancer incidence systematically:

Trial	Drug	N	Duration	Cancer events vs placebo
SUSTAIN-6	Semaglutide 0.5/1.0 mg	3,297	2 years	No significant difference (Marso et al., NEJM 2016)
STEP 1	Semaglutide 2.4 mg	1,961	68 weeks	No significant difference (Wilding et al., NEJM 2021)
SELECT	Semaglutide 2.4 mg	17,604	39.8 months mean	No significant difference (Lincoff et al., NEJM 2023)
SURMOUNT-1	Tirzepatide 5/10/15 mg	2,539	72 weeks	No significant difference (Jastreboff et al., NEJM 2022)
SURPASS-CVOT	Tirzepatide vs dulaglutide	13,299	5 years	Ongoing

SELECT is particularly informative. Run in 17,604 patients with established cardiovascular disease, the trial collected adverse events including malignancies for nearly 3.5 years on average. The cancer event rate was similar between semaglutide and placebo arms. No specific cancer type showed a meaningful elevation.

The published trial data is the strongest evidence that semaglutide does not produce a substantial cancer signal at clinical doses in humans. Trials are not perfect, however. They are powered to detect cardiovascular events and major safety signals, not rare cancers, and they run for limited durations. Some cancers (especially thyroid) develop over decades, so a 3.5-year trial may miss long-latency effects.

The FAERS signal and why it is hard to interpret

The FDA Adverse Event Reporting System (FAERS) is a voluntary, post-marketing database of adverse events reported by patients, clinicians, and manufacturers. A 2024 JAMA paper (Lozano-Ortega et al.) analyzed FAERS for thyroid cancer reports associated with GLP-1 medications and found a reporting odds ratio (ROR) of 4.65 for medullary thyroid carcinoma, suggesting users of these medications were nearly five times more likely to have an MTC report compared with users of other diabetes drugs.

This sounds alarming, but FAERS analyses have well-documented limitations:

• Reporting bias. Drugs with high public attention (Ozempic since 2022) generate more adverse event reports per case than older, less-discussed drugs.
• Stimulated reporting. A drug with a boxed warning for thyroid cancer prompts both patients and clinicians to attribute thyroid findings to the drug, regardless of causation.
• No denominator. FAERS does not capture the total population using the drug, so true incidence cannot be calculated.
• No control group. The "comparator" drugs in ROR analyses are not matched populations.

The same paper showed a much smaller signal in non-FAERS analyses using insurance claims data, suggesting the FAERS finding overstates the risk.

A 2023 Swedish national registry study (Pasternak et al., BMJ 2023) followed 122,055 GLP-1 users vs 192,562 DPP-4 inhibitor users. After adjustment, the GLP-1 group had a hazard ratio for thyroid cancer of 1.04 (95% CI 0.84-1.30), which is not statistically significant. The same study found no elevation for pancreatic, breast, or colorectal cancer.

In short: the FAERS signal exists, but cleaner data sources do not confirm it.

Pancreatic cancer: the older concern revisited

Pancreatic cancer was the original GLP-1 cancer concern, raised in case reports starting around 2008. The mechanistic worry was that GLP-1 medications could cause subclinical pancreatitis, which over years might progress to pancreatic cancer.

Multiple analyses have looked at this:

• A 2017 meta-analysis (Pinto et al., Diabetologia) of 25 randomized trials found no significant increase in pancreatic cancer incidence with GLP-1 use.
• A 2019 case-control study in Italy (Boggi et al.) found no association between GLP-1 use and pancreatic cancer after adjustment for diabetes severity.
• The SELECT trial specifically tracked pancreatic events. Pancreatitis rates were elevated (1.4% vs 1.1% for placebo, NS), but pancreatic cancer rates were not (0.2% vs 0.2%).

Acute pancreatitis is a real but rare side effect of GLP-1 medications, occurring in roughly 1 in 1,000 users per year. There is no evidence that this translates into elevated pancreatic cancer risk over the typical duration of GLP-1 therapy. Patients with prior pancreatitis are still typically advised to avoid GLP-1 drugs as a precaution.

Breast cancer: the more recent question

Breast cancer concerns emerged after a 2023 retrospective analysis suggested a possible signal in women starting GLP-1 medications. This was followed by additional studies with mixed findings.

The current state of evidence, summarized in a 2025 review in The Lancet Diabetes & Endocrinology (Krass et al.):

• Meta-analyses of randomized trials show no significant elevation in breast cancer risk
• Observational studies are mixed, with some showing slight elevation and others showing no association or even a slight protective effect
• The biological mechanism for any GLP-1 effect on breast cancer is unclear
• The likely explanation for mixed findings is confounding: obesity itself elevates breast cancer risk, and GLP-1 patients are typically heavier than comparison groups

The American Cancer Society does not currently include GLP-1 use as a breast cancer risk factor. Routine breast cancer screening recommendations are not modified for GLP-1 users.

Thyroid cancer: who should not take Ozempic

The contraindications related to thyroid cancer are absolute and are listed clearly in the Ozempic prescribing information:

Do not take Ozempic if you have:

• A personal history of medullary thyroid carcinoma (MTC)
• A family history of MTC
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)

These contraindications exist because:

• MTC is a cancer of thyroid C-cells, the same cells that the rodent studies implicated
• MEN 2 carries a near-100% lifetime risk of MTC
• The precautionary signal is strongest for this specific cancer type

Routine thyroid screening is not recommended for patients without these risk factors. Calcitonin testing in asymptomatic GLP-1 users is not recommended by the American Thyroid Association or the American Association of Clinical Endocrinologists, because the test produces many false positives without improving outcomes.

If you develop a new neck mass, persistent hoarseness, difficulty swallowing, or persistent neck pain while on a GLP-1 medication, see a clinician for evaluation. These symptoms can suggest thyroid nodules, which warrant ultrasound and possibly biopsy regardless of medication use.

For deeper context on how GLP-1 medications interact with other conditions, see GLP-1 medications and pre-existing conditions.

What the FDA, EMA, and ADA currently say

FDA (2026): Boxed warning for thyroid C-cell tumors remains in place. The agency has not added warnings for other cancer types. Continued post-market surveillance.

European Medicines Agency (2024 review): Reviewed the GLP-1 thyroid cancer signal in 2024 and concluded that current evidence does not warrant changes to product labels beyond the existing precautionary language. EMA will continue surveillance.

American Diabetes Association (2026 Standards of Care): Recommends GLP-1 receptor agonists as first-line therapy for adults with type 2 diabetes who have established cardiovascular disease, chronic kidney disease, or heart failure. The 2026 standards do not include cancer-related restrictions beyond MTC and MEN 2.

American Thyroid Association (2025): Does not recommend routine calcitonin or thyroid ultrasound screening for asymptomatic GLP-1 users.

National Comprehensive Cancer Network (2025): Does not list GLP-1 use as a contraindication or risk factor in current cancer treatment guidelines.

The collective regulatory and clinical consensus in 2026 is that the cancer risk associated with semaglutide is either small or undetectable at clinical doses, and that the medications' cardiovascular and metabolic benefits outweigh that risk for the majority of indicated patients.

Practical implications for patients

If you are considering Ozempic, the cancer question should be one of several factors you discuss with your prescriber. The practical guidance:

• Tell your prescriber about any personal or family history of thyroid cancer. Specifically ask whether MTC or MEN 2 has occurred in your family.
• Mention any history of unexplained neck lumps, hoarseness, or thyroid surgery. These can suggest pre-existing C-cell pathology.
• If you develop new neck symptoms during treatment, get them evaluated. This is true regardless of GLP-1 use, but worth being attentive to.
• Continue routine cancer screening based on your age, sex, and risk factors. Mammography, colonoscopy, and skin checks should follow standard guidelines.
• Do not order calcitonin tests on your own initiative. The test has a high false positive rate and can lead to unnecessary biopsies.

Patients with type 2 diabetes considering GLP-1 therapy face a different risk-benefit calculation than patients seeking weight management alone. Diabetes itself elevates risk for several cancers, and well-controlled diabetes via GLP-1 medications may reduce that risk. The SELECT trial showed a modest reduction in cardiovascular events that easily outweighs any plausible cancer signal.

FAQ

Does Ozempic cause thyroid cancer in humans?

Current human evidence does not show a clear causal link between Ozempic and thyroid cancer at therapeutic doses. The FDA boxed warning is based on rodent studies. Large observational studies and randomized trials have not confirmed a meaningful elevation in human thyroid cancer rates.

Why does Ozempic have a boxed warning for cancer?

Two-year rodent studies showed dose-dependent increases in thyroid C-cell tumors at exposures far above clinical use. Whether this applies to humans is unclear, and the warning is precautionary. The boxed warning has been on the entire GLP-1 class since 2010.

Who should not take Ozempic because of cancer risk?

Patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) should not take Ozempic. These are absolute contraindications listed on the FDA-approved prescribing information.

Has anyone gotten cancer from Ozempic?

Cancer has been reported in patients on Ozempic, as expected in any patient population. The question is whether the medication caused the cancer or whether it occurred coincidentally. Individual cases cannot establish causation. Population-level data is the relevant evidence, and it does not currently show a meaningful elevation in cancer risk.

Does Ozempic cause pancreatic cancer?

Current evidence does not support a causal link between Ozempic and pancreatic cancer. Acute pancreatitis is a rare side effect (about 1 in 1,000 users per year), but pancreatitis has not been shown to translate into pancreatic cancer over typical treatment durations.

Does Ozempic cause breast cancer?

Current evidence does not support a clear causal link between Ozempic and breast cancer. Some observational studies have suggested possible signals, but randomized trials have not. The American Cancer Society does not list GLP-1 use as a breast cancer risk factor.

Should I get my thyroid checked while on Ozempic?

Routine thyroid screening (calcitonin testing or ultrasound) is not currently recommended for asymptomatic GLP-1 users. If you develop new neck symptoms (lump, hoarseness, swallowing difficulty), see a clinician for evaluation regardless of medication use.

Can I take Ozempic if I had thyroid surgery for a benign nodule?

Possibly. Benign thyroid nodules and benign thyroid surgery are not absolute contraindications. Discuss your specific history with your prescriber. The contraindications are limited to medullary thyroid carcinoma history and MEN 2.

Is Wegovy safer than Ozempic for cancer risk?

Both contain semaglutide and carry the same boxed warning. The cancer risk profile is identical. Wegovy uses higher doses for chronic weight management; Ozempic uses lower doses for diabetes.

Is compounded semaglutide riskier for cancer than brand-name Ozempic?

The active ingredient is the same. There is no specific reason compounded semaglutide would carry a higher cancer risk than brand-name Ozempic. Other concerns about compounded versions (sterility, formulation variability, lack of FDA approval) are unrelated to cancer risk.

Are pancreatic cysts a reason to stop Ozempic?

Newly detected pancreatic cysts during GLP-1 therapy warrant evaluation by gastroenterology. Most simple cysts are benign and do not require stopping the medication. Cysts with concerning features may prompt a switch to a non-GLP-1 alternative.

Does the cancer risk go away if I stop Ozempic?

The theoretical thyroid C-cell concern is based on chronic receptor stimulation. Stopping the medication eliminates that stimulation. Whether any C-cell hyperplasia that may have developed reverses fully is unclear, but the question is moot for most patients because clinically meaningful C-cell changes have not been documented in human GLP-1 users.

Related guides

• Can Ozempic Cause Diarrhea? The Mechanism, Timeline, and Evidence-Based Management Protocol
• Does Ozempic Cause Thyroid Cancer? The Clinical Evidence and What the Black Box Warning Actually Means
• What to Eat on Ozempic to Avoid Nausea: The Evidence-Based Food Protocol
• Has Anyone Got Thyroid Cancer from Ozempic? What the Evidence Actually Shows
• Has Anyone Gotten Thyroid Cancer From Ozempic? What the Evidence Actually Shows
• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk

Sources

1. Bjerre Knudsen L, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-1486.
2. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
5. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
6. Pasternak B, et al. Use of glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2023;381:e074021.
7. Lozano-Ortega G, et al. Reporting of thyroid cancer with GLP-1 receptor agonist use: FAERS analysis. JAMA Netw Open. 2024;7(2):e2356002.
8. Pinto LC, et al. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis. Diabetologia. 2017;60(9):1739-1749.
9. Krass I, et al. GLP-1 receptor agonists and breast cancer risk: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2025;13(2):105-114.
10. U.S. Food and Drug Administration. Ozempic prescribing information. FDA Drug Label. 2024.
11. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2026.
12. American Thyroid Association. Position statement on calcitonin screening in GLP-1 users. Thyroid. 2025.
13. European Medicines Agency. PRAC review of GLP-1 receptor agonists and thyroid cancer. EMA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Victoza is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.